|
|
|
|
CALLISTO PHARMACEUTICALS RECEIVES STTR/NIH GRANT
AWARD
New York, New York – October 7, 2003 – Callisto
Pharmaceuticals, Inc. (OTCBB: CLSP
- News) announced that it has received a $265,000 Small Business
Technology Transfer Research grant from the National Institutes
of Health for studies on Atiprimod, Callisto’s lead drug candidate for multiple
myeloma. The Principal and Co-Principal Investigators of the grant entitled “Atiprimod
to Treat Multiple Myeloma and Bone Resorption” are Dr. Gary S. Jacob,
Chief Executive Officer, Callisto Pharmaceuticals, and Dr. Kenneth C. Anderson,
Director of the Jerome Lipper Multiple Myeloma Center of the Dana-Farber
Cancer Institute, respectively. Studies will utilize unique in vitro and
in-vivo methods and animal models at Dana-Farber Cancer Institute and at
Callisto to explore Atiprimod’s pharmacological activity and mechanism
of action. “We are pleased to be collaborating with Dr. Anderson and
his team on this project which will help us to better define the biological
activity of Atiprimod,” says Dr. Gary S. Jacob, CEO of Callisto Pharmaceuticals,
Inc.
About Callisto Pharmaceuticals, Inc.
Callisto is a biopharmaceutical company focused
on the development of drugs to treat multiple myeloma, other
cancers and osteolytic bone disease. Callisto’s
lead drug candidate, Atiprimod, is a small-molecule, orally available
drug with antiproliferative and antiangiogenic activity. Atiprimod
successfully completed Phase I clinical trials in rheumatoid arthritis patients
and Callisto
filed an IND on September 23, 2003 with the U.S. Food and Drug
Administration on Atiprimod to enter a Phase I/IIa clinical trial
in multiple
myeloma patients.
The drug is also being explored as an agent to treat osteolytic
bone disease. In addition, Callisto has programs focused on the
development of an analog
of the human intestinal hormone, uroguanylin, to treat colon cancer,
and drugs to protect against staphylococcal and streptococcal
bioweapons, as
a protection against the devastating effects of toxic shock syndrome.
Callisto has two operating subsidiaries, Callisto Research Labs,
LLC and Synergy
Pharmaceuticals Inc.
About Dana-Farber Cancer Institute
Dana-Farber Cancer Institute is a principal teaching affiliate of the Harvard
Medical School and is among the leading cancer research and care centers
in the United States. It is a founding member of the Dana-Farber/Harvard
Cancer Center (DF/HCC), designated a comprehensive cancer center by the
National Cancer Institute.
Included in this release are “forward-looking: statements. Such
statements are indicated by words such as “expect,” “should,” “anticipate” and
similar words indicating uncertainty in facts and figures. Although Callisto
believes that the expectations reflected in such forward-looking statements
are reasonable, it can give no assurance that such expectations reflected
in such forward-looking statements will prove to have been correct. Callisto’s
actual results could differ materially from those anticipated in
the forward-looking statements as a result of various factors.
|
|
|
|
|